Smith Group Asset Management’s Puma Biotechnology PBYI Stock Holding History

Smith Group Asset Management’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-3,440	Closed	-$203K	–	446
2018 Q2	$203K	Buy	3,440 +200	+6%	+$11.6K	0.01%	251
2018 Q1	$220K	Sell	3,240 -2,300	-42%	-$172K	0.01%	247
2017 Q4	$548K	Hold	5,540	–	–	0.02%	200
2017 Q3	$663K	Hold	5,540	–	–	0.02%	192
2017 Q2	$484K	Hold	5,540	–	–	0.01%	216
2017 Q1	$206K	Hold	5,540	–	–	0.01%	268
2016 Q4	$170K	Hold	5,540	–	–	0.01%	272
2016 Q3	$371K	Buy	+5,540	New	+$280K	0.01%	205

Other funds holding PBYI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Smith Group Asset Management's PBYI Position: Q3 2018 in Review

Smith Group Asset Management sold out of Puma Biotechnology (PBYI) in Q3 2018, closing a stake of 3,440 shares — an estimated $203K sold.

Smith Group Asset Management first reported a position in PBYI in Q3 2016 and held it in 8 quarters. The position peaked at $663K in Q3 2017. 156 funds tracked by Wall St. Rank hold PBYI as of Q3 2018.

Smith Group Asset Management reported no remaining Puma Biotechnology position as of Q3 2018 after selling out during the quarter.
Smith Group Asset Management sold 3,440 Puma Biotechnology shares in Q3 2018, an estimated $203K.
Smith Group Asset Management first reported a position in Puma Biotechnology in Q3 2016 and held it in 8 quarters.
Smith Group Asset Management's Puma Biotechnology position peaked at $663K in Q3 2017.
156 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2018.

Based on Smith Group Asset Management's 13F filing for Q3 2018, filed 2 Nov 2018.